Exposure-related interstitial lung disease Advocacy Hub | UniteRare

At a Glance

Live from database

💊

2FDA treatments

💰

1Open funds

Regulatory Watchboard

1 event

Sep 2019Ofev: FDA approved

OFEV is indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD).

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

Total programs

Open now

Patient Assistance Programs1

Actemra

Genentech, Inc.

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

2 FDA-approved

Ofev

(NINTEDANIB)Orphan drug

Boehringer Ingelheim Pharmaceuticals, Inc.

12.1 Mechanism of Action Nintedanib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRT...

Approved Sep 2019FDA label ↗

Actemra

(tocilizumab)Orphan drugstandard

Genentech, Inc.

Interleukin-6 Receptor Antagonist [EPC]

12.1 Mechanism of Action Tocilizumab binds to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), and has been shown to inhibit IL-6-m...

FDA label ↗

View full treatment details on disease page →